Guangzhou Pharmaceutical Co., Ltd.
Established on September 1, 1997, with a registered capital of RMB 810.9 million, it is manufactured by eight proprietary Chinese medicine subsidiaries of Guangzhou Pharmaceutical Group Co., Ltd. The company and three pharmaceutical trading companies were reorganized and established. It is mainly engaged in the manufacturing and sales of Chinese patent medicines, the wholesale, retail, import and export of Chinese medicines, Western medicines and medical devices, and the research and development of natural medicines and biomedicine. On October 21, 1997, the company's H shares were sold to the Hong Kong public at 1.65 yuan per share, and 219.9 million H shares were issued, with a total raised amount of approximately HKD 362,835,000. When it was listed in Hong Kong, it signed a "Trademark License Agreement" with the company's controlling shareholder, Guangzhou Pharmaceutical Group. Pursuant to the Trademark License Agreement, GPHL has granted the Company and its subsidiaries an exclusive license to use 38 trademarks owned by GPHL on all current and future products produced by the Group for an initial period of use until the Trademark License Agreement is signed. 10 years from the date. Unless GPHL issues a notice of termination three months before the initial expiration date, the trademark license agreement may be automatically renewed by the Company for a further 10 years upon expiration. Pursuant to the Trademark License Agreement, the Company pays an annual license fee for the use of the licensed trademark, which is calculated based on 0.1 of the Company's total net sales as shown in the audited annual financial statements prepared under PRC Accounting Standards, and is paid quarterly.
In January 1998, the new factory of its subsidiary Guangzhou Chenliji Pharmaceutical Factory was put into operation.
In April 1998, our company formally signed an agreement with Beijing University of Chinese Medicine to jointly build a Traditional Chinese Medicine Technology Innovation Center to strengthen cooperation in the development of new drugs and the improvement and application of traditional Chinese medicine engineering technology. It will speed up the research and development of the company's new products and the application of new technologies.
In April 1998, our company formally signed an agreement with Hong Kong Hexing White Flower Oil Company, and our company became the exclusive general distributor of "Hexing White Flower Oil" in mainland China.
With the approval of the board of directors in December 1999, the company spent 15 million yuan to implement the SAP-R3 management system at the Guangzhou Pharmaceutical Headquarters and its affiliated enterprises, and hired Deloitte Management Company as an implementation consultant to officially launch the ERP project.
On June 17, 1999, the company established a CI leadership group, issued a CI manual, and formally notified subordinate companies to implement a comprehensive corporate identification system, strictly follow the CI manual standards, and unify corporate advertising and publicity behaviors.
In March 2000, due to poor management of Guangzhou Zhongsheng Pharmaceutical Factory, the company decided to be managed by Guangzhou No. 1 Traditional Chinese Medicine Factory.
On September 25, 2000, on the basis that Guangzhou Zhongsheng Pharmaceutical Factory was managed by Guangzhou Zhongsheng Pharmaceutical Factory, Guangzhou Pharmaceutical decided to merge it with Guangzhou Zhongsheng Pharmaceutical Factory.
On October 18, 2000, Guangzhou Pharmaceutical held its second extraordinary general meeting of shareholders, at which the resolution regarding A shares was reviewed and approved. On December 22, we received approval from the China Securities Regulatory Commission, approving our company to issue no more than 100 million additional A shares.
On November 2, 2000, Guangzhou Pharmaceutical and Guangzhou Air Force Hospital formally signed an agreement at the White Swan Hotel on the cooperative development of "anti-hepatitis B virus dual plasmid gene vaccine" to develop biological genetic drugs. The field has taken its first step.
On February 6, 2001, Guangzhou Pharmaceutical A shares were officially listed for trading on the Shanghai Stock Exchange. The first-hand transaction price was 13.00 yuan/share. The company’s total share capital increased from 732.9 million shares at the beginning of 2001. It increased to 810.9 million shares in the first half of 2001. The proportion of state-owned shares in total equity dropped from 70 to 62.26, and the proportion of circulating shares in total equity increased from 30 to 36.74.
February 21, 2001 , agreed that Beijing University of Chinese Medicine would transfer its 30% stake in the Guangjing Traditional Chinese Medicine Technology Innovation Center to Guangzhou Institute of Pharmaceutical Industry, and the Guangjing Traditional Chinese Medicine Technology Innovation Center would be renamed.
On August 27, 2001, Guangzhou Pharmaceutical established Guangzhou Baidi Biopharmaceutical Co., Ltd.
The company has a registered capital of 20 million yuan, of which Guangzhou Pharmaceutical holds 82 shares, Guangzhou Institute of Pharmaceutical Industry holds 10 shares, and the management of Guangzhou Baidi Biopharmaceutical Co., Ltd. personally holds 8 shares.
On September 27, 2001, Guangzhou Pharmaceutical held the eighth meeting of the second board of directors, which reviewed and approved the purchase of Guangzhou Pharmaceutical Group Co., Ltd. by Guangzhou Pharmaceutical Company, a wholly-owned subsidiary of the company, at a price of RMB 39,239,480. Proposal on related transactions of Suikang Building owned by Guangzhou Medical Materials Supply Company, a wholly-owned subsidiary of the company.
On October 19, 2001, Guangzhou Pharmaceutical signed a contract with the independent third party Oplmind International Holding Limited of the United Kingdom. Both parties agreed to establish Guangzhou Pharmaceutical (UK) Co., Ltd. in London, England in the form of cooperation. The company invested in the exclusive right to use the brands "Guangzhou Pharmaceutical" and "Caizhilin" in the United Kingdom and European countries, which will account for 20% of the company's total share capital. Oplmind International Holding Limited invested in cash, which will account for 20% of the company's total share capital. 80 of share capital.
On December 31, 2001, Guangzhou Pharmaceutical Company and Guangzhou No. 1 Traditional Chinese Medicine Factory, both subsidiaries of the Guangzhou Pharmaceutical Department, were successfully restructured. Guangzhou Pharmaceutical Company was restructured into "Guangzhou Pharmaceutical Co., Ltd." The company holds about 90% of the shares, and the two legal entities Jingxiutang and Pan Gaoshou and the senior managers, middle managers and technical backbones of the pharmaceutical company hold about 10% of the shares in total. Guangzhou No. 1 Traditional Chinese Medicine Factory was restructured into "Guangzhou Zhongyi Pharmaceutical Co., Ltd.". The company holds approximately 90 shares. The senior managers, middle managers and technical backbones of Guangzhou Pharmaceutical Co., Ltd. and Guangzhou Zhongyi Pharmaceutical Co., Ltd. collectively hold approximately 90 shares. 10. The successful restructuring of the above two enterprises marks a breakthrough for Guangzhou Pharmaceutical in establishing a modern enterprise.
On February 6, 2004, Guangzhou Pharmaceutical Co., Ltd. and Guangzhou Pharmaceutical Group Co., Ltd. signed the Property Rights Transaction Contract. According to the contract, the Company invested RMB 3,888,713.99 to acquire the 51% equity interest of Guangzhou Pharmaceutical Group Yingbang Marketing Co., Ltd. held by Guangzhou Pharmaceutical Group, accounting for the net asset value of Yingbang Company on the base date of asset evaluation on October 31, 2003. 51 of RMB 7,624,929.40. After the acquisition is completed, the Company will hold 51% equity interest in Yingbang Company, while GPHL will hold 49% equity interest in Yingbang Company. On May 25, 2004, Hanfang Company held a board meeting to make a resolution on the company's capital increase and share expansion. After the capital increase is completed, the registered capital of Hanfang Company will increase from RMB 83.2843 million to RMB 127.7643 million, and Guangzhou Pharmaceutical will hold 70.04 shares. On the same day, Hanfang Company held the first extraordinary shareholders' meeting in 2004. The original shareholders of Hanfang Company all agreed that Guangzhou Pharmaceutical would increase capital in the form of cash by RMB 44.48 million to the company based on the company's original share capital structure. Guangzhou Hanfang Modern Chinese Medicine Research and Development Co., Ltd. is a subsidiary of Guangzhou Pharmaceutical Co., Ltd.
On November 8, 2004, Guangzhou Pharmaceutical and GPHL signed the "Supplementary Agreement to the Trademark License Agreement" (the "Supplementary Agreement"). Pursuant to the supplementary agreement, Guangzhou Pharmaceutical agreed to terminate the exclusive use rights of five trademarks currently used by Wanglaoji Pharmaceutical products, and Guangzhou Pharmaceutical Group also agreed to license the Group's exclusive use rights of 36 other trademarks. After the capital increase from Tongxing Pharmaceutical to Wanglaoji Pharmaceutical is completed, Wanglaoji Pharmaceutical will no longer be a subsidiary of the Company, but an associated company of the Company. Therefore, Wanglaoji Pharmaceutical cannot use the licensed trademark in the trademark license agreement. According to the supplementary agreement, after the capital increase is completed and Wanglaoji Pharmaceutical changes to a foreign-invested joint-stock company, the company will be entitled to receive 47% of the annual licensing fees collected by GPHL from Wanglaoji Pharmaceutical.
On February 23, 2006, Guangzhou Pharmaceutical Co., Ltd.’s subsidiaries Xingqun Pharmaceutical, Zhongyi Pharmaceutical, Wanglaoji Pharmaceutical, Pangaoshou Pharmaceutical, Qixing Pharmaceutical, Chenliji Pharmaceutical and Jing Xiutang Pharmaceutical signed the "Agreement on the Establishment of Guangzhou Pharmaceutical Football Club Co., Ltd." with Guangzhou Baiyunshan Pharmaceutical Co., Ltd. and its six affiliated companies.
According to the agreement, all shareholders contributed RMB 20 million in cash to jointly establish Guangzhou Medical Football Club Co., Ltd.
In January 2007, the company's subsidiaries transferred their equity interests in Guangzhou Pharmaceutical Co., Ltd. and increased the capital of the pharmaceutical company.